GATM Polymorphism Associated with the Risk for Statin-Induced Myopathy Does Not Replicate in Case-Control Analysis of 715 Dyslipidemic Individuals

Statin-induced myopathy (SIM) is the most common reason for discontinuation of statin therapy. A polymorphism affecting the gene encoding glycine amidinotransferase (GATM rs9806699 G > A) was previously associated with reduced risk for SIM. Our objective was to replicate the GATM association in a large, multicenter SIM case-control study. Mild and severe SIM cases and age- and gender-matched controls were enrolled. Participants were genotyped, and associations were tested (n = 715) using chi-square and logistic regression with consideration for SIM severity and exclusion of subjects with potentially confounding comedications. The minor allele (A) frequencies of GATM rs9806699 in the controls (n = 106), mild SIM (n = 324), and severe SIM (n = 285) cases were 0.26, 0.28, and 0.29, respectively (p = 0.447). The unadjusted odds ratio for the A allele for any SIM (mild or severe) was 1.14 (0.82–1.61; p = 0.437), which remained nonsignificant in all models. Our results do not replicate the association between GATM rs9806699 and SIM. [Display omitted] •The association of GATM rs9806699 with statin-induced myopathy was not replicated•GATM rs9806699 allele/genotype frequencies were similar in SIM cases and controls•Meta-analysis yielded a marginal, but null, association of GATM rs9806699 with SIM Statin-induced myopathy (SIM) is the most common reason for discontinuation of statin therapy. While a polymorphism affecting the gene encoding glycine amidinotransferase (GATM rs9806699) was previously associated with reduced SIM, Luzum et al. do not replicate this association in a large, multicenter SIM case-control study including 715 individuals.